Login / Signup

Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial.

Raphael KochLianne M HavemanRuth Lydia LadensteinBenedicte BrichardHeribert JuergensSona CyprovaHenk van den BergWolf HassenpflugAnna RaciborskaTorben EkDaniel BaumhoerGerlinde EgererLeo KagerMarleen RenardPéter HauserStefan E G BurdachJudith V M G BovéeAngela M HongPeter ReichardtJarmila KruseováArne StreitbürgerThomas KuhneTorsten KesslerMarie BernkopfTrude Butterfaß-BahloulCatharina DhoogeSebastian BauerJános KissMichael PaulussenFiona BonarAndreas RanftBeate TimmermannJelena RasconVolker ViethJukka KanervaAndreas FaldumWolfgang HartmannLars HjorthVivek A BhadriMarkus MetzlerAndré B P van KuilenburgUta Dirksen
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • clinical trial
  • prognostic factors
  • peritoneal dialysis
  • study protocol
  • patient reported
  • replacement therapy